title: A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.
abstract: National healthcare systems as well as local institutions generally reimburse numerous off-label uses of anticancer drugs, but an explicit framework for managing these payments is still lacking. As in the case of on-label uses, an optimal management of off-label uses should be aimed at a direct proportionality between cost and clinical benefit. Within this framework, assessing the incremental cost/effectiveness ratio becomes mandatory, and measuring the magnitude of the clinical benefit (e.g. gain in overall survival or progression-free survival) is essential.This paper discusses how the standard principles of cost-effectiveness and value-for-money can be applied to manage the reimbursement of off-label treatments in oncology. It also describes a detailed operational scheme to appropriately implement this aim. Two separate approaches are considered: a) a trial-based approach, which is designed for situations where enough information is available from clinical studies about the expected effectiveness of the off-label treatment; b) an individualized payment-by-results approach, which is designed for situations in which adequate information on effectiveness is lacking; this latter approach requires that each patient receiving off-label treatment is followed-up to determine individual outcomes and tailor the extent of payment to individual results.Some examples of application of both approaches are presented in detail, which have been extracted from a list of 184 off-label indications approved in 2010 by the Region of tuscany in italy. these examples support the feasibility of the two methods proposed.In conclusion, the scheme described in this paper represents an operational solution to an unsettled problem in the area of oncology drugs.
authors.affiliation: Laboratorio di Farmacoeconomia, c/o University of Florence, Via Guimaraes 5-7, 59100 Prato, Italy. messoriandrea@interfree.it
authors.forename: A
authors.initials: A
authors.lastname: Messori
authors.forename: V
authors.initials: V
authors.lastname: Fadda
authors.forename: S
authors.initials: S
authors.lastname: Trippoli
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics* / Q000627:therapeutic use*; D003362:Cost-Benefit Analysis / Q000379:methods / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D006801:Humans; D007558:Italy; D009369:Neoplasms / Q000188:drug therapy*; D056687:Off-Label Use / Q000191:economics*; D012051:Reimbursement Mechanisms / Q000191:economics*
chemical_list: D000970:Antineoplastic Agents